Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Shares Outstanding (Weighted Average) (2022 - 2025)

TriSalus Life Sciences' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $37.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 418.35% year-over-year to $37.9 million; the TTM value through Dec 2025 reached $37.9 million, up 418.35%, while the annual FY2025 figure was $37.9 million, 418.35% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $37.9 million in Q4 2025 per TLSIW's latest filing, up from $7.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $37.9 million in Q4 2025 to a low of $309609.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $15.3 million, with a median of $10.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 92.86% in 2023, then surged 5191.04% in 2024.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $309609.0 in 2022, then surged by 1493.41% to $4.9 million in 2023, then surged by 48.2% to $7.3 million in 2024, then surged by 418.35% to $37.9 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Shares Outstanding (Weighted Average) are $37.9 million (Q4 2025), $7.4 million (Q3 2025), and $32.9 million (Q2 2025).